Evogene (EVGN) Depreciation & Amortization (CF) (2013 - 2026)
Evogene (EVGN) posted Depreciation & Amortization (CF) of $202000.0 for Q1 2026, down 23.19% sequentially from $263000.0 in Q4 2025, and down 34.84% YoY from $310000.0 in Q1 2025.
Evogene (EVGN) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Evogene has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $202000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 34.84% year-over-year to $202000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 13.45% YoY) and the FY2025 annual result came in at $1.1 million, down 17.16% from the prior year.
- Depreciation & Amortization (CF) retreated to $202000.0 in Q1 2026 per EVGN's latest filing, from $263000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $426000.0 in Q1 2024 and troughed at $202000.0 in Q1 2026.
- A 5-year average of $341941.2 and a median of $348000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) slumped 49.76% in 2024, then soared 34.45% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $396000.0 in 2022, then rose by 5.56% to $418000.0 in 2023, then fell by 16.75% to $348000.0 in 2024, then declined by 24.43% to $263000.0 in 2025, then retreated by 23.19% to $202000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $202000.0, $263000.0, and $281000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 202,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 202,000.00 |
| Mar 31, 2026 | 202,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Jun 30, 2025 | 290,000.00 |
| Jun 30, 2025 | 290,000.00 |
| Mar 31, 2025 | 310,000.00 |
| Mar 31, 2025 | 310,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Sep 30, 2024 | 209,000.00 |
| Sep 30, 2024 | 209,000.00 |
| Jun 30, 2024 | 330,000.00 |
| Jun 30, 2024 | 330,000.00 |
| Mar 31, 2024 | 426,000.00 |
| Mar 31, 2024 | 426,000.00 |
| Dec 31, 2023 | 418,000.00 |
| Dec 31, 2023 | 418,000.00 |